Physician profile
James E Petre
NPI 1619973989
$128,049.80
in general payments reported to CMS, 2019-2025
60 companies · $2,088 in 2025
The $2,088 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53K · 2020: $15K · 2021: $19K · 2022: $9,823 · 2023: $16K · 2024: $12K · 2025: $2,088.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Food and Beverage: $7,468 · Travel and Lodging: $332 · Education: $83.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,865.00 |
| Food and Beverage | $7,467.69 |
| Travel and Lodging | $332.31 |
| Education | $83.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $52,599.94 | 2019-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $40,374.97 | 2019-2025 | Farxiga, Fasenra, Tezspire |
| Idorsia Pharmaceuticals US INC | $13,307.00 | 2023-2024 | Quviviq |
| Esperion Therapeutics, INC. | $5,370.62 | 2020-2021 | |
| Allergan, INC. | $3,112.38 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $2,098.15 | 2019-2024 | Xarelto |
| Abbvie INC. | $1,529.47 | 2021-2025 | |
| Novo Nordisk INC | $1,494.04 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $985.60 | 2019-2025 | Jardiance, Synjardy |
| Pfizer INC. | $786.61 | 2019-2025 | |
| Lilly USA, LLC | $711.69 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $537.96 | 2020-2025 | Trelegy Ellipta, Pediarix, Bexsero |
| Astellas Pharma US INC | $445.92 | 2019-2025 | Veozah, Myrbetriq |
| Axsome Therapeutics, INC. | $370.39 | 2023-2025 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $319.23 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Petre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.